GNPX

Company Overview — What Does Genprex, Inc. Do?

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. Genprex, Inc. (GNPX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO J. Rodney Varner and employs approximately 20 people. With a market capitalization of $4M, GNPX is one of the notable companies in the Healthcare sector.

Genprex, Inc. (GNPX) Stock Rating — Reduce (April 2026)

As of April 2026, Genprex, Inc. receives a Reduce rating with a composite score of 33.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.GNPX ranks #3,521 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Genprex, Inc. ranks #550 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GNPX Stock Price and 52-Week Range

Genprex, Inc. (GNPX) currently trades at $1.20. The stock lost $0.10 (7.7%) in the most recent trading session. The 52-week high for GNPX is $12.97, which means the stock is currently trading -90.8% from its annual peak. The 52-week low is $0.14, putting the stock 756.8% above its annual trough. Recent trading volume was 482K shares, suggesting relatively thin trading activity.

Is GNPX Overvalued or Undervalued? — Valuation Analysis

Genprex, Inc. (GNPX) carries a value factor score of 7/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.56x, versus the sector average of 2.75x.

At current multiples, Genprex, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Genprex, Inc. Profitability — ROE, Margins, and Quality Score

Genprex, Inc. (GNPX) earns a quality factor score of 13/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -210.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -164.9% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GNPX Debt, Balance Sheet, and Financial Health

Genprex, Inc. has a debt-to-equity ratio of 28.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.84x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $1M.

GNPX has a beta of 0.55, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Genprex, Inc. is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Genprex, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Genprex, Inc. reported revenue of $0 and earnings per share (EPS) of $-17.40. Net income for the quarter was $-17M. Operating income came in at $-16M.

In FY 2025, Genprex, Inc. reported revenue of $0 and earnings per share (EPS) of $-17.40. Net income for the quarter was $-16M. Operating income came in at $-16M.

In Q3 2025, Genprex, Inc. reported revenue of $0 and earnings per share (EPS) of $-5.00. Net income for the quarter was $-4M. Operating income came in at $-3M.

In Q2 2025, Genprex, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.17. Net income for the quarter was $-5M. Operating income came in at $-5M.

Over the past 8 quarters, Genprex, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing GNPX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GNPX Dividend Yield and Income Analysis

Genprex, Inc. (GNPX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GNPX Momentum and Technical Analysis Profile

Genprex, Inc. (GNPX) has a momentum factor score of 69/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 67/100 reflects moderate short selling activity.

GNPX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Genprex, Inc. (GNPX) ranks #550 out of 838 stocks based on the Blank Capital composite score. This places GNPX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GNPX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GNPX vs S&P 500 (SPY) comparison to assess how Genprex, Inc. stacks up against the broader market across all factor dimensions.

GNPX Next Earnings Date

No upcoming earnings date has been announced for Genprex, Inc. (GNPX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GNPX? — Investment Thesis Summary

The quantitative profile for Genprex, Inc. suggests caution. The quality score of 13/100 flags below-average profitability. The value score of 7/100 indicates premium valuation. Price momentum is positive at 69/100, suggesting the trend favors buyers. High volatility (stability score 25/100) increases portfolio risk.

In summary, Genprex, Inc. (GNPX) earns a Reduce rating with a composite score of 33.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GNPX stock.

Related Resources for GNPX Investors

Explore more research and tools: GNPX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GNPX head-to-head with peers: GNPX vs AZN, GNPX vs SLGL, GNPX vs VMD.